Evommune, Inc.

Quick facts

Phase 2 pipeline

• EVO101
• EVO301 · Immunology
  EVO301 is a monoclonal antibody targeting CD22.
• Oral EVO756

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Evommune, Inc. portfolio CI brief
• Evommune, Inc. pipeline updates RSS